Nippon Shinyaku Sets Up Promotion Agreement With Pfizer For Tramal In Japan
This article was originally published in PharmAsia News
Executive Summary
Nippon Shinyaku and Pfizer signed a license agreement allowing Pfizer to begin Japan promotion of the cancer and chronic pain drug Tramal (tramadol) sold by Nippon Shinyaku and the tramadol sustained formulation NS-24, which has been in Phase III trials since April 2012.